A Prospective Randomized Multicenter Study on the Impact of [ 18 F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer

被引:0
作者
Evangelista, Laura [1 ,2 ]
Zattoni, Fabio [3 ,4 ]
Burei, Marta [5 ,16 ]
Bertin, Daniele [5 ]
Borsatti, Eugenio [6 ]
Baresic, Tanja [6 ]
Farsad, Mohsen [7 ]
Trenti, Emanuela [8 ]
Bartolomei, Mirco [9 ]
Panareo, Stefano [9 ,10 ]
Urso, Luca [9 ,11 ]
Trifiro, Giuseppe [12 ]
Brugola, Elisabetta [12 ]
Chierichetti, Franca [13 ]
Donner, Davide [13 ,14 ]
Gallan, Mauro [1 ,15 ]
Setti, Lucia [15 ]
Del Bianco, Paola [17 ]
Magni, Giovanna [17 ]
De Salvo, Gian Luca [17 ]
Novara, Giacomo [3 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
[2] IRCCS Humanitas Res Hosp, Nucl Med Unit, Rozzano, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol, Urol Unit, Padua, Italy
[4] Univ Padua, Dept Med, DIMED, Padua, Italy
[5] Veneto Inst Oncol, Nucl Med Unit, Padua, Italy
[6] Ctr Riferimento Oncol, Dept Radiat Oncol, Nucl Med Unit, Aviano, Italy
[7] Cent Hosp Bolzano, Dept Nucl Med, Bolzano, Italy
[8] Cent Hosp Bolzano, Dept Urol, Bolzano, Italy
[9] Univ Hosp, Nucl Med Unit, Ferrara, Italy
[10] Azienda Osped Univ Modena, Nucl Med Unit, Modena, Italy
[11] Univ Ferrara, Dept Environm & Prevent Sci, Ferrara, Italy
[12] ICS Maugeri IRCCS Spa SB, Nucl Med Unit, Pavia, Italy
[13] Santa Chiara Hosp, Nucl Med Unit, APSS Prov Autonoma Trento, Trento, Italy
[14] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[15] Humanitas Gavazzeni, Nucl Med Unit, Bergamo, Italy
[16] Angelo Hosp, Nucl Med Unit, Venice, Italy
[17] Veneto Inst Oncol, Clin Res Unit, Padua, Italy
关键词
fluorocholine; prostate cancer; diagnostic imaging; disease management; prognosis; RADICAL RETROPUBIC PROSTATECTOMY; POSITRON-EMISSION-TOMOGRAPHY; BIOCHEMICAL RECURRENCE; CHOLINE; PROGRESSION; GUIDELINES; DISEASE;
D O I
10.2967/jnumed.123.267355
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This study aimed to compare the efficacy of [F-18]F-choline PET/CT with conventional imaging for staging and managing intermediate- to high-risk prostate cancer (PCa). The primary objective was to assess the ability of PET/CT with [F-18]F-choline to identify lymph node and systemic involvement during initial staging. Secondary objectives included evaluating the impact of [F-18]F-choline PET/CT on unnecessary local treatments and assessing the safety of [F-18]F-choline agents. Additionally, the study aimed to analyze recurrence-free survival and overall survival 5 y after randomization. Methods: A prospective controlled, open, randomized multicenter phase III trial involving 7 Italian centers was conducted. Eligible patients with intermediate- to high-risk PCa were randomized in a 1:1 ratio. Two groups were formed: one undergoing conventional imaging (abdominopelvic contrast-enhanced CT and bone scanning) and the other receiving conventional imaging plus [F-18]F-choline PET/CT. The study was terminated prematurely; however, all the endpoints were thoroughly analyzed and enriched. Results: Between February 2016 and December 2020, 256 patients were randomly assigned. In total, 236 patients (117 in the control arm and 119 in the experimental arm) were considered for the final assessment. In the experimental arm, the sensitivity for lymph node metastases, determined by final pathology and serial prostate-specific antigen evaluations, was higher than in the control arm (77.78% vs. 28.57% and 65.62% vs. 17.65%, respectively). The [F-18]F-choline was tolerated well. The use of [F-18]F-choline PET/CT resulted in an approximately 8% reduction in unnecessary extended lymphadenectomy compared with contrast-enhanced CT. Additionally, [F-18]F-choline PET/CT had a marginal impact on 5-y overall survival, contributing to a 4% increase in survival rates. Conclusion: In the initial staging of PCa, [F-18]F-choline PET/CT exhibited diagnostic performance superior to that of conventional imaging for detecting metastases. [F-18]F-choline PET/CT reduced the rate of unnecessary extensive lymphadenectomy by up to 8%. These findings support the consideration of discontinuing conventional imaging for staging PCa.
引用
收藏
页码:1013 / 1020
页数:8
相关论文
共 26 条
  • [1] Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued rise of biochemical failure after 5 years
    Amling, CL
    Blute, ML
    Bergstralh, EJ
    Seay, TM
    Slezak, J
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 2000, 164 (01) : 101 - 105
  • [2] 18F Choline PET/CT in the Preoperative Staging of Prostate Cancer in Patients with Intermediate or High Risk of Extracapsular Disease: A Prospective Study of 130 Patients
    Beheshti, Mohsen
    Imamovic, Larisa
    Broinger, Gabriele
    Vali, Reza
    Waldenberger, Peter
    Stoiber, Franz
    Nader, Michael
    Gruy, Bernhard
    Janetschek, Guenter
    Langsteger, Werner
    [J]. RADIOLOGY, 2010, 254 (03) : 925 - 933
  • [3] The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT
    Beheshti, Mohsen
    Vali, Reza
    Waldenberger, Peter
    Fitz, Friedrich
    Nader, Michael
    Hammer, Josef
    Loidl, Wolfgang
    Pirich, Christian
    Fogelman, Ignac
    Langsteger, Werner
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2009, 11 (06) : 446 - 454
  • [4] [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse:: experience in 100 consecutive patients
    Cimitan, Marino
    Bortolus, Roberto
    Morassut, Sandro
    Canzonieri, Vincenzo
    Garbeglio, Antonio
    Baresic, Tanja
    Borsatti, Eugenio
    Drigo, Annalisa
    Trovo, Mauro G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (12) : 1387 - 1398
  • [5] Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes
    Cookson, Michael S.
    Aus, Gunnar
    Burnett, Arthur L.
    Canby-Hagino, Edith D.
    D'Amico, Anthony V.
    Dmochowski, Roger R.
    Eton, David T.
    Forman, Jeffrey D.
    Goldenberg, S. Larry
    Hernandez, Javier
    Higano, Celestia S.
    Kraus, Stephen R.
    Moul, Judd W.
    Tangen, Catherine
    Thrasher, J. Brantley
    Thompson, Ian
    [J]. JOURNAL OF UROLOGY, 2007, 177 (02) : 540 - 545
  • [6] DeGrado TR, 2001, CANCER RES, V61, P110
  • [7] Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
    Djaileb, Loic
    Armstrong, Wesley R.
    Thompson, Daniel
    Gafita, Andrei
    Farolfi, Andrea
    Rajagopal, Abhejit
    Grogan, Tristan R.
    Nguyen, Kathleen
    Benz, Matthias R.
    Hotta, Masatoshi
    Barbato, Francesco
    Ceci, Francesco
    Schwarzenboeck, Sarah M.
    Unterrainer, Marcus
    Zacho, Helle D.
    Juarez, Roxanna
    Cooperberg, Matthew
    Carroll, Peter
    Washington, Samuel
    Reiter, Robert E.
    Eiber, Matthias
    Herrmann, Ken
    Fendler, Wolfgang P.
    Czernin, Johannes
    Hope, Thomas A.
    Calais, Jeremie
    [J]. EUROPEAN UROLOGY, 2023, 84 (06) : 588 - 596
  • [8] Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [18F] choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate-tohigh-risk prostate cancer: A retrospective analysis
    Evangelista, Laura
    Cimitan, Marino
    Zattoni, Fabio
    Guttilla, Andrea
    Zattoni, Filiberto
    Saladini, Giorgio
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2015, 49 (05) : 345 - 353
  • [9] Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool
    Gandaglia, Giorgio
    Barletta, Francesco
    Robesti, Daniele
    Scuderi, Simone
    Rajwa, Pawel
    Rivas, Juan Gomez
    Ibanez, Laura
    Soeterik, Timo F. W.
    Bianchi, Lorenzo
    Afferi, Luca
    Kesch, Claudia
    Darr, Christopher
    Guo, Hongqian
    Zhuang, Junlong
    Zattoni, Fabio
    Fendler, Wolfgang
    Marra, Giancarlo
    Stabile, Armando
    Amparore, Daniele
    Huebner, Nicolai A.
    Giesen, Alexander
    Joniau, Steven
    Schiavina, Riccardo
    Brunocilla, Eugenio
    Mattei, Agostino
    Dal Moro, Fabrizio
    Sierra, Jesus Moreno
    Porpiglia, Francesco
    Picchio, Maria
    van den Bergh, Roderick
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Briganti, Alberto
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (06): : 543 - 552
  • [10] Giona S., 2021, Prostate Cancer, P1, DOI DOI 10.36255/EXONPUBLICATIONS.PROSTATECANCER.EPIDEMIOLOGY.2021